share_log

DENTSPLY SIRONA (NASDAQ:XRAY) Has A Somewhat Strained Balance Sheet

デンツプライシロナ (ナスダック:XRAY) はやや緊張したバランスシートを持っています

Simply Wall St ·  12/03 06:46

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know worries about.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. Importantly, DENTSPLY SIRONA Inc. (NASDAQ:XRAY) does carry debt. But is this debt a concern to shareholders?

Why Does Debt Bring Risk?

Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. Ultimately, if the company can't fulfill its legal obligations to repay debt, shareholders could walk away with nothing. However, a more common (but still painful) scenario is that it has to raise new equity capital at a low price, thus permanently diluting shareholders. Having said that, the most common situation is where a company manages its debt reasonably well - and to its own advantage. When we think about a company's use of debt, we first look at cash and debt together.

What Is DENTSPLY SIRONA's Net Debt?

As you can see below, at the end of September 2024, DENTSPLY SIRONA had US$2.23b of debt, up from US$2.03b a year ago. Click the image for more detail. However, it also had US$296.0m in cash, and so its net debt is US$1.94b.

big
NasdaqGS:XRAY Debt to Equity History December 3rd 2024

How Healthy Is DENTSPLY SIRONA's Balance Sheet?

We can see from the most recent balance sheet that DENTSPLY SIRONA had liabilities of US$1.54b falling due within a year, and liabilities of US$2.59b due beyond that. On the other hand, it had cash of US$296.0m and US$671.0m worth of receivables due within a year. So its liabilities total US$3.17b more than the combination of its cash and short-term receivables.

This deficit is considerable relative to its market capitalization of US$3.91b, so it does suggest shareholders should keep an eye on DENTSPLY SIRONA's use of debt. This suggests shareholders would be heavily diluted if the company needed to shore up its balance sheet in a hurry.

We use two main ratios to inform us about debt levels relative to earnings. The first is net debt divided by earnings before interest, tax, depreciation, and amortization (EBITDA), while the second is how many times its earnings before interest and tax (EBIT) covers its interest expense (or its interest cover, for short). Thus we consider debt relative to earnings both with and without depreciation and amortization expenses.

DENTSPLY SIRONA has a debt to EBITDA ratio of 3.2 and its EBIT covered its interest expense 3.5 times. This suggests that while the debt levels are significant, we'd stop short of calling them problematic. Another concern for investors might be that DENTSPLY SIRONA's EBIT fell 11% in the last year. If that's the way things keep going handling the debt load will be like delivering hot coffees on a pogo stick. There's no doubt that we learn most about debt from the balance sheet. But ultimately the future profitability of the business will decide if DENTSPLY SIRONA can strengthen its balance sheet over time. So if you want to see what the professionals think, you might find this free report on analyst profit forecasts to be interesting.

But our final consideration is also important, because a company cannot pay debt with paper profits; it needs cold hard cash. So it's worth checking how much of that EBIT is backed by free cash flow. Happily for any shareholders, DENTSPLY SIRONA actually produced more free cash flow than EBIT over the last three years. There's nothing better than incoming cash when it comes to staying in your lenders' good graces.

Our View

DENTSPLY SIRONA's EBIT growth rate and interest cover definitely weigh on it, in our esteem. But its conversion of EBIT to free cash flow tells a very different story, and suggests some resilience. We should also note that Medical Equipment industry companies like DENTSPLY SIRONA commonly do use debt without problems. Looking at all the angles mentioned above, it does seem to us that DENTSPLY SIRONA is a somewhat risky investment as a result of its debt. That's not necessarily a bad thing, since leverage can boost returns on equity, but it is something to be aware of. The balance sheet is clearly the area to focus on when you are analysing debt. But ultimately, every company can contain risks that exist outside of the balance sheet. Case in point: We've spotted 1 warning sign for DENTSPLY SIRONA you should be aware of.

Of course, if you're the type of investor who prefers buying stocks without the burden of debt, then don't hesitate to discover our exclusive list of net cash growth stocks, today.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする